Seeking Alpha

Keryx (KERX -3.6%) notes that the Taxpayer Relief Act delays by two years, until January 2016,...

Keryx (KERX -3.6%) notes that the Taxpayer Relief Act delays by two years, until January 2016, the inclusion of oral-only dialysis-related drugs in the money that Medicare pays facilities in a single bundle for dialysis treatment. Keryx CEO Ron Bentsur says this is a good thing for the firm's Zerenex drug, although investors don't seem to be convinced. (PR)
Comments (2)
  • biofan
    , contributor
    Comments (3) | Send Message
     
    Any opinions from KERX stockholders on latest announcement?
    3 Jan 2013, 11:35 AM Reply Like
  • DougRk
    , contributor
    Comments (1516) | Send Message
     
    Reading the press release, it sounds like the CEO is claiming that since orals won't be paid in a bundle, KERX will have to stand on its own. Thereby proving its worth? Sounds convoluted and spin-ish to me. Am long. Leaning toward getting out post-phase 3 results now.
    6 Jan 2013, 06:17 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|